# US 2023/0265151 A1 · Gip/glp1 co-agonist compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265151 A1
- Document ID: US20230265151A1
- Status: Published application
- Kind: A1
- Application number: 17/794,128
- Filed: 2021-01-21
- Published: 2023-08-24
- Earliest claimed: 2020-01-23
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Jorge ALSINA-FERNANDEZ; Robert Andrew BROWN; Robert Chadwick CUMMINS; Mohamed Elsayed Hamed ELSAYED; Andrea Renee GEISER; Xianyin LAI; Hongchang QU; Brian Morgan WATSON
- Web page: https://patentgrep.com/patent/US20230265151A1

## CPC

- C07K 14/605: Glucagons
- A61K 38/2235: {Secretins}
- A61K 38/26: Glucagons
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/645: Secretins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds having activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The present invention also relates to compounds having an extended duration of action at each of these receptors. Furthermore, the present invention relates to compounds that may be administered orally. These compounds may be useful in the treatment of type 2 diabetes mellitus (“T2DM”). These compounds may be useful in the treatment of obesity.

## Claims

### Claim 1

A compound of the formula:
X1X2EGTX6TSDX10X11X12X13LDX16X17AQX20X21X22IX24X25LIX28GX30 (SEQ ID NO:505) wherein
X1 is selected from the group consisting of Y and R1Y;
R1 is an Ac modification of the N-terminal amino group;
X2 is Aib;
X6 is selected from the group consisting of αMeF and αMeF(2F);
X10 is selected from the group consisting of 4Pal, Y, αMeF, αMeF(2F), αMeL, αMeV, Ac4c, Ac5c, Ac6c, Bip, 1Nal, 2Nal, OMeY, hTyr, Nle, V, 4CPhe, ChG, ChA, Bzt, 2FA, 4TAA, 2TA, 3TA, and KZ1;
X11 is selected from the group consisting of S, αMeS, Aib, G, Dap, Ac5c, and T1e;
X12 is selected from the group consisting of I and KZ1;
X13 is selected from the group consisting of αMeL and αMeF;
X16 is Orn;
X17 is selected from the group consisting of Q, I, and KZ1;
X20 is selected from the group consisting of Aib, Orn, 4Pal, αMeF, Ac5c, and Ac6c;
X21 is selected from the group consisting of E, KZ1, G, Orn, and 4Pal;
X22 is selected from the group consisting of F, 2ClPhe, 3ClPhe, 2FPhe, 3FPhe, 3,5FPhe, 1Nal, 2Nal, αMeF(2F), ChA, Bzt, and αMeF;
X24 is selected from the group consisting of D-Glu, E, G, and KZ1;
X25 is selected from the group consisting of Y, αMeY, αMeF, and KZ1;
X28 is selected from the group consisting of E, Orn, and KZ1;
X30 is selected from the group consisting of G, Orn, KZ1, K(Z1)R6, OrnR2, and GR2;
R2 is selected from the group consisting of X31, X31SSG(SEQ ID NO:5), X31SSG-R3 (SEQ ID NO:6), X31SSGX35PPPX39 (SEQ ID NO:7), X31SSGX35PPPX39R3 (SEQ ID NO:8), X31SSGX35PPPX39X40 (SEQ ID NO:9), X31SSGX35PPPX39X40R3 (SEQ ID NO: 10), and a modification of the c-terminal group wherein the modification is NH2; R6 is selected from the group consisting of PSSG(SEQ ID NO:506), PSSG-R3 (SEQ ID NO:507), PSSGX35PPPX39 (SEQ ID NO:508), PSSGX35PPPX39R3 (SEQ ID NO:509), PSSGX35PPPX39X40 (SEQ ID NO:510), PSSGX35PPPX39X40R3 (SEQ ID NO:511), and a modification of the c-terminal group wherein the modification is NH2; X31 is selected from the group consisting of P, and KZ1;
X35 is selected from the group consisting of A and Orn;
X39 is selected from the group consisting of S and Orn;
X40 is KZ1,
R3 is a modification of the C-terminal group, wherein the modification is NH2;
wherein two, and only two, of X10, X12, X17, X21, X24, X25, X28, X30, X31, and X40 are KZ1 or K(Z1)R6;
Z1 is selected from the group consisting of R5 and -R4R5;
R4 is a linker; and
R5 is a fatty acid; or
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1 wherein
X30 is selected from the group consisting of G, Orn, KZ1, and GR2; and
R2 is selected from the group consisting of X31SSG (SEQ ID NO:5), X31SSG-R3 (SEQ ID NO:6), X31SSGX35PPPX39 (SEQ ID NO:7), X31SSGX35PPPX39R3 (SEQ ID NO:8), X31SSGX35PPPX39X40 (SEQ ID NO:9), X31SSGX35PPPX39X40R3 (SEQ ID NO: 10), and a modification of the c-terminal group wherein the modification is NH2.

### Claim 3 (depends on 2)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 2, wherein Z1 is -R4R5.

### Claim 4 (depends on 3)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 3 wherein R5 is selected from the group consisting of -CO-(CH2)12-CO2H, CO-(CH2)14-CO2H, -CO-(CH2)10-CO2H, -(10-(4-carboxyphenoxy)decanoyl), -(4-(4-iodophenyl)butanoyl), -(4-(4-tert-butylphenyl)butanoyl), -CO-(CH2)14-CH3, -CO-(CH2)12-CH3, -CO-(CH2)10-CH3, -(7-(4-carboxyphenoxy)heptanoyl), -(11-(4-carboxyphenoxy)undecanoyl), -(12-(4-carboxyphenoxy)dodecanoyl), and -(8-(4-carboxyphenoxy)octanoyl).

### Claim 5 (depends on 3)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 3 wherein R5 is selected from the group consisting of
-CO-(CH2)12-CO2H, -CO-(CH2)10-CO2H, -(10-(4-carboxyphenoxy)decanoyl), -(4-(4-iodophenyl)butanoyl), -(4-(4-tert-butylphenyl)butanoyl), -CO-(CH2)14-CH3, -CO-(CH2)12-CH3, -CO-(CH2)10-CH3, -(7-(4-carboxyphenoxy)heptanoyl), and -(8-(4-carboxyphenoxy)octanoyl).

### Claim 6 (depends on 3)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 3 wherein R5 is selected from the group consisting of
CO-(CH2)14-CO2H, -(11-(4-carboxyphenoxy)undecanoyl), and -(12-(4-carboxyphenoxy)dodecanoyl).

### Claim 7 (depends on 3)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 3 wherein R4 is -(εK)a1-(γ-Glu)a2-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)a3-(εK)b1-(γ-Glu)b2-;
a1 is selected from the group consisting of 0, 1, and 2;
a2 is selected from the group consisting of 0, 1, and 2;
a3 is selected from the group consisting of 0, 1, 2, and 3;
b1 is 0 or 1; and
b2 is 0 or 1.

### Claim 8 (depends on 3)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 3 wherein R4 is selected from the group consisting of
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)2)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(εK)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(εK)-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-Trx-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-,
-PEG3-(γ-Glu)-,
-PEG4-(γ-Glu)-,
-PEG5-(γ-Glu)-,
-PEG6-(γ-Glu)-,
-Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
-Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
-(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
-(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-,
-(εK)-(γ-Glu)-,
-(εK)-(γ-Glu)-(γ-Glu)-,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-,
-(εK)-(εK)-(γ-Glu)-,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(y-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-, and
(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(y-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-.

### Claim 9 (depends on 3)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 3 wherein R4 is selected from the group consisting of
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(εK)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(εK)-(γ-Glu)-,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-,
-(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-,
-(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-,
-(εK)-(γ-Glu)-,
-(εK)-(γ-Glu)-(γ-Glu)-,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-,
-(εK)-(εK)-(γ-Glu)-,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-, and
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-.

### Claim 10 (depends on 2)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 2, wherein Z1 is selected from the group consisting of
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)10-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-iodophenyl)butanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-tert-butylphenyl)butanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)14-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)10-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)14-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)10-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-CO-(CH2)14-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(εK)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(εK)-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-CO-(CH2)12-CO2H,
-(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H,
-(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H,
-(εK)-(γ-Glu)-CO-(CH2)12-CO2H,
-(εK)-(γ-Glu)-(γ-Glu)-CO-(CH2)12-CO2H,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-CO-(CH2)12-CO2H,
-(εK)-(εK)-(γ-Glu)-CO-(CH2)12-CO2H,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(7-(4-carboxyphenoxy)heptanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(8-(4-carboxyphenoxy)octanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(4-(4-tert-butylphenyl)butanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(11-(4-carboxyphenoxy)undecanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-CO-(CH2)12-CO2H,
-PEG3-(γ-Glu)-CO-(CH2)12-CO2H,
-PEG4-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-CO-(CH2)10-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(11-(4-carboxyphenoxy)undecanoyl,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)14-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-CO-(CH2)12-CO2H,
-Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H,
-Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-PEG4-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-PEG3-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-CO-(CH2)12-CO2H,
-PEG6-(γ-Glu)-CO-(CH2)12-CO2H,
-PEG5-(γ-Glu)-CO-(CH2)12-CO2H,
-PEG6-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-PEG5-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-Trx-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-Trx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)2-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)2-(10-(4-carboxyphenoxy)decanoyl),
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H, and
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl).

### Claim 11 (depends on 10)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 10 wherein Z1 is selected from the group consisting of:
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)10-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-iodophenyl)butanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-tert-butylphenyl)butanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)14-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)10-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)14-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)io-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-CO-(CH2)14-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(εK)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(εK)-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(εK)-(γ-Glu)-CO-(CH2)12-CO2H,
-(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H,
-(εK)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H,
-(εK)-(γ-Glu)-CO-(CH2)12-CO2H,
-(εK)-(γ-Glu)-(γ-Glu)-CO-(CH2)12-CO2H,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-CO-(CH2)12-CO2H,
-(εK)-(εK)-(γ-Glu)-CO-(CH2)12-CO2H,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(y-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(7-(4-carboxyphenoxy)heptanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(8-(4-carboxyphenoxy)octanoyl), and
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(y-Glu)-(4-(4-tert-butylphenyl)butanoyl).

### Claim 12 (depends on 10)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 10 wherein Z1 is selected from the group consisting of:
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(11-(4-carboxyphenoxy)undecanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-CO-(CH2)12-CO2H,
-PEG3-(γ-Glu)-CO-(CH2)12-CO2H,
-PEG4-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)3-(γ-Glu)-CO-(CH2)10-CH3,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(11-(4-carboxyphenoxy)undecanoyl,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)14-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-CO-(CH2)12-CO2H,
-Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H,
-Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Ahx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-Ahx-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-Aoc-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-PEG4-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-PEG3-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Aoc-CO-(CH2)12-CO2H,
-PEG6-(γ-Glu)-CO-(CH2)12-CO2H,
-PEG5-(γ-Glu)-CO-(CH2)12-CO2H,
-PEG6-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-PEG5-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-Trx-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-Trx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ-Glu)-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-Trx-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)2-CO-(CH2)12-CO2H,
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)2-(10-(4-carboxyphenoxy)decanoyl),
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H,
-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl),
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-CO-(CH2)12-CO2H, and
-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl).

### Claim 13 (depends on 1)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 1 wherein:
X1 is Y;
X6 is αMeF(2F);
X10 is selected from the group consisting of 4Pal, Y, and KZ1;
X11 is selected from the group consisting of S, αMeS, and Aib;
X12 is I;
X13 is αMeL;
X16 is Orn;
X17 is selected from the group consisting of I and KZ1;
X20 is Aib;
X21 is E or KZ1;
X22 is selected from the group consisting of F and αMeF;
X24 is selected from the group consisting of D-Glu and KZ1;
X25 is αMeY;
X28 is selected from the group consisting of E and KZ1;
X30 is selected from the group consisting of G and GR2;
R2 is selected from the group consisting of X31SSGX35PPPX39 (SEQ ID NO:7),
X31SSGX35PPPX39R3 (SEQ ID NO:8), and X31SSGX35PPPX39X40 (SEQ ID NO:9), and a modification of the c-terminal group wherein the modification is NH2;
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 13)

A compound or pharmaceutically acceptable salt thereof, as claimed by claim 13 wherein
X30 is GR2; and
R2 is selected from the group consisting of X31SSGX35PPPX39 (SEQ ID NO:7), X31SSGX35PPPX39R3 (SEQ ID NO:8), and X31SSGX35PPPX39X40 (SEQ ID NO:9).

### Claim 15 (depends on 13)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 13 wherein X17 and X31 are each KZ1.

### Claim 16 (depends on 13)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 13 wherein X17 and X24 are each KZ1.

### Claim 17 (depends on 13)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 13 wherein X17 and X21 are each KZ1.

### Claim 18 (depends on 13)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 13 wherein X17 and X28 are each KZ1.

### Claim 19 (depends on 13)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 13 wherein X21 and X28 are each KZ1.

### Claim 20 (depends on 13)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 13 wherein X24 and X28 are each KZ1.

### Claim 21 (depends on 13)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 13 wherein X17 and X40 are each KZ1.

### Claim 22 (depends on 13)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 13 wherein X21 and X40 are each KZ1.

### Claim 23 (depends on 1)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 1 wherein the compound is selected from the group consisting of
Y-Aib-EGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H)SSGAPPPS-NH2,
Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl))SSGAPPPS-NH2,
Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-iodophenyl)butanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-iodophenyl)butanoyl))SSGAPPPS-NH2,
Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-tert-butylphenyl)butanoyl))SSGAPPPS-NH2, and
Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)10-CH3)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)10-CH3)SSGAPPPS-NH2.

### Claim 24 (depends on 23)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 23 wherein the compound is Y-Aib-EGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)10-CH3)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)10-CH3)SSGAPPPS-NH2.

### Claim 25 (depends on 23)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 23 wherein the compound is Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-tert-butylphenyl)butanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-tert-butylphenyl)butanoyl))SSGAPPPS-NHz.

### Claim 26 (depends on 23)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 23 wherein the compound is Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-iodophenyl)butanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(4-(4-iodophenyl)butanoyl))SSGAPPPS-NH2.

### Claim 27 (depends on 23)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 23 wherein the compound is Y-Aib-EGT-aMeF(2F)-TSD-4Pal-SI-aMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl))AQ-Aib-EFI-(D-Glu)-aMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-(10-(4-carboxyphenoxy)decanoyl))SSGAPPPS-NH2.

### Claim 28 (depends on 23)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 23 wherein the compound is Y-Aib-EGT-αMeF(2F)-TSD-4Pal-SI-αMeL-LD-Orn-K((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H)AQ-Aib-EFI-(D-Glu)-αMeY-LIEGGK((2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(γ-Glu)-CO-(CH2)12-CO2H)SSGAPPPS-NH2.

### Claim 29 (depends on 1)

A method for treating a condition selected from the group consisting of type 2 diabetes mellitus, obesity, NAFLD, nonalcoholic steatohepatitis, dyslipidemia, and metabolic syndrome, comprising administering to a patient in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1.

### Claim 30 (depends on 1)

A method for treating obesity, comprising administering to a patient in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1.

### Claim 31 (depends on 1)

A method for providing therapeutic weight loss, comprising administering to a subject in need thereof, an effective amount of a compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1.

### Claim 32 (depends on 1)

A method for treating type 2 diabetes mellitus comprising administering to a subject in need thereof, an effective amount of the compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1.

### Claim 33 (depends on 1)

A pharmaceutical composition comprising the compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1, and at least one pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 34 (depends on 1)

A pharmaceutical composition as claimed by claim 1 wherein the composition is administered as a subcutaneous injection.

### Claim 35 (depends on 1)

A pharmaceutical composition as claimed by claim 1 wherein the composition is administered orally.

### Claim 36 (depends on 1)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1 for use as a medicament.

### Claim 37 (depends on 1)

A compound, or pharmaceutically acceptable salt thereof, as claimed by claim 1 for use in treating a condition selected from the group consisting of type 2 diabetes mellitus, obesity, NAFLD, nonalcoholic steatohepatitis, dyslipidemia, and metabolic syndrome.

### Claim 38 (depends on 1)

A compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1 for use in treating type 2 diabetes mellitus.

### Claim 39 (depends on 1)

The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1 in the manufacture of a medicament for treating a condition selected from the group consisting of type 2 diabetes mellitus, obesity, NAFLD, nonalcoholic steatohepatitis, dyslipidemia, and metabolic syndrome.

### Claim 40 (depends on 1)

The use of a compound, or a pharmaceutically acceptable salt thereof, as claimed by claim 1 in the manufacture of a medicament for treating type 2 diabetes mellitus.
